Despite detectable KLF14 expression in a range of tissues, these cis and trans associations were completely adipose specific, with Regulatory variants at KLF14 influence type 2 diabetes risk via a female-specific effect on adipocyte size and body composition To investigate the mechanisms underlying these associations, we explored the molecular, cellular and whole-body effects of T2D-associated alleles near KLF14. We show that KLF14 diabetes-risk alleles act in adipose tissue to reduce KLF14 expression and modulate, in trans, the expression of 385 genes. We demonstrate, in human cellular studies, that reduced KLF14 expression increases pre-adipocyte proliferation but disrupts lipogenesis, and in mice, that adipose tissue-specific deletion of Klf14 partially recapitulates the human phenotype of insulin resistance, dyslipidemia and T2D. We show that carriers of the KLF14 T2D risk allele shift body fat from gynoid stores to abdominal stores and display a marked increase in adipocyte cell size, and that these effects on fat distribution, and the T2D association, are female specific. The metabolic risk associated with variation at this imprinted locus depends on the sex both of the subject and of the parent from whom the risk allele derives.
T he replicated genome-wide significant T2D association signal at chr7q32.3 maps to a 45-kb recombination interval that extends from 3 kb to 48 kb upstream of KLF14 1, 2 ( Fig. 1a-c) . In previous work based on microarray-derived RNAexpression data, KLF14, which encodes an imprinted transcription factor, was exposed as the likely cis-effector gene for this locus in subcutaneous adipose tissue 1 and was shown to be a trans regulator of a program of adipose tissue expression 3 . The KLF family of zinc-finger binding proteins has wide-ranging regulatory roles in biological processes such as proliferation, differentiation and growth 4, 5 . However, little is known about KLF14, a single-exon gene whose transcription is limited to the maternally inherited chromosome in embryonic, extra-embryonic and adult tissue in humans and mice 6 .
Results
Adipose-specific regulation of KLF14 mediates the T2D association. Using RNA-based next-generation sequencing (RNA-seq) data from subcutaneous adipose biopsies collected from 766 female twin members of the TwinsUK cohort 7 , we confirmed the cis-expression quantitative trait locus (eQTL) (using the SNP rs4731702 T2D risk allele C as the reference; β = -0.56; P = 1.8 × 10 −36
) and identified a 38-fold-expanded trans network of 385 genes (false-discovery rate (FDR) < 5%) ( Fig. 2 and Supplementary Table 1 ). The cis and trans effects at KLF14 were robust and were replicated in three independent studies of expression in subcutaneous adipose tissue (MGH 8 , METSIM 9 and deCODE ) (a), HDL-C levels (n = 99,900) (ref.
27
) (b) and KLF14 mRNA abundance in adipose tissue (n = 766 women; TwinsUK) (c). Circles represent genotyped and imputed DNA variants; colors indicate LD r 2 values with the index SNP rs4731702 (key). The red asterisk (below) indicates the position of methylation probe cg02385110. The blue box contains the putative enhancer shown in d. Association between genotype and KLF14 expression was assessed using mixed-effects models, correcting for family structure and relevant covariates (Methods). Uncorrected P values are displayed. d, Chromatinstate annotations for the KLF14 locus across 93 reference epigenomes (rows) for cell and tissue types profiled by the Roadmap Epigenomics and ENCODE projects. Colors correspond to chromatin states (yellow, enhancer; red, promoter; as in ref. 43 ). The blue box contains the putative enhancer. Chromosome coordinates correspond to UCSC Genome Browser build hg19. ESC, embryonic stem cell; HSC, hematopoietic stem cell; iPSC, induced pluripotent stem cell. e-i, KLF14 mRNA abundance (e,f) and methylation of probe cg02385110 (g-i) in concurrently sampled adipose tissue (n = 720 (e) and n = 595 (g)), skin (n = 606 (f) and n = 414 (h)) and whole blood (n = 368 (not shown) and n = 289 (i)) from participants of the TwinsUK study, based on rs4731702 genotype (CC, risk-allele homozygotes). KLF14 expression was undetectable in whole blood. Box plots display the median, with 'hinges' corresponding to the first and third quartiles; whiskers extend from the 'hinge' to the largest value no further than 1.5× the inter-quartile range, with values beyond shown as outliers. Associations were assessed by linear regression, with correction for family structure and relevant covariates (Methods).
specific-the paternally inherited allele had no effect on KLF14 expression (Supplementary Fig. 1 and Supplementary Table 4 ). All other genes within 300 kb of the interval are also imprinted but paternally expressed, confirming KLF14 as the likely mediator of the T2D association at this locus.
We first sought to refine the location of the causal variant(s) responsible for the associations noted above. The T2D association could not be resolved beyond a set of 29 SNPs in high mutual linkage disequilibrium (LD) (r 2 > 0.94 in the UK10K project); the apparent European specificity of the T2D association 15 precludes trans-ethnic fine mapping. The ancestral T2D risk allele varies in global frequency within the 1000 Genomes Project populations (EUR, 54%; ASN, 69%; AMR, 58%; AFR, 73%), but we detected no evidence of positive selection (Supplementary Fig. 2 and Supplementary Note 1). We used chromatin-state maps to annotate the associated interval and identified a ~1.6-kb enhancer ~5 kb upstream of KLF14. This enhancer encompasses 5 of the 29 associated variants and shows marked tissue specificity: in ChromHMM software predictions from ENCODE 16 and Roadmap 17 , and it is annotated as active in 10 (out of 127) cell types and tissues, 3 of which are derived from adipose tissue, including adipocytes and adipose tissue-derived mesenchymal stem cells (Fig. 1d) . The enhancer is also active in certain blood cells, but there was no corresponding cis-eQTL [18] [19] [20] , making it unlikely that transcriptional regulation in blood cells contributes to the genome-wide association study (GWAS) phenotypes. There were no other adipose active enhancers in the region. GNB1   GATA3   EPBALL5  ARHGDIO   CHD3   IFT52   CDK2API   SVIL   TUBA8   MMPI5   PHF20   C17ofr96   CIIorf24   HABP4 LGALSI2 C20orf194   BEX4   PPP2R2A   RNASET2   RAB3GAP   MAGED2   EXYD1   TMEMI39  PBXIP1   NCALD  ADCY6   FAM109A   NPHP3   RRAGD   SLC38A3   FZD9   FAM102B   SIAE   ACAA1   GSK3A   TUBB   MX1   DHPS   SIX2   PTPRU   SLC25A23   SLC25A10   RUNDC3B   GYS1   RIMS3   INPP5B   ABCB6  LDHA   GRPEL1   RHGEFI6  FAM98A  KLF13   RBFA  ELOVL5   MBOAT7  CROCC  PISD  TFAP4   FUT10  SPTAN1   DK2AP2   SNA11  FLOT2   ESRRG  STARD10   ART5   RASLI0B   RABIF  SDC3   C19orf2   ABHDI5  TPMT   MSRA   DIS3L   STK11   HSF4   SLC5A6   KLFI5   FAM53A   NUCBI   REEP6   KCTDI0   SLC41A1   KIAA1958   PDXK   SREBFI   PNPLA3   LSS   NSDHL   LZTFLI   PGP   C3orf25   HES6  PCYT2   CETN2   TM7SF2   ARSD   MMAB   RAB36   PLA266   FAM36A   WTIP   MVK  TKT   FAM59B   TBX4   GLBIL   PACSI   CTDSPL   TLE1   FGERL1   USMG5   CS   CKB  B4GALT2   SLC26A6   YPEL5   CA5B   PRMT2   KLF14   ALDH6AI   EPB41   RRP9   PEX26   CCL28   SLCI9AI   C17orf39   SNTB1   MTMRI0   CCHDI  MCART1   NOTCH3   GCDH  DDAH2   RHGAP2   LHPP   APEH   NTRK3   OAF   TTLL7   POR   PTHIR   KCND3   AMOT   FGF9   SLC442   SLC2AI   CD151   PYGM   PPME1   PHKA2   KIAA0664   TMEM220   DOCK9   UNCI3B   ESYTI   PPFIBP2   ST3GAL6   FLAD1   PTDSS2   TRIM62   PRDX2   CILP2   SLC2A4   LRP3   NR2F1   PTPDC1   PLEKHG3   R3HDM1  DFNA5   SCMHI   RTF1   LBP   ACO1   IPO9   OCEL1   GPR153   HR   RASA2   SLC38A4   IZUM04   NIN   UBTD2   MYL3   SALL1   CIDEB   CYB5RI   FAM40B ) . Solid lines link KLF14 to trans genes containing KLF14 binding sites; dashed lines link SREBF1 to trans genes containing SREBF1 binding sites. c, Replication of the KLF14 trans network in three independent adipose-tissue cohorts: METSIM (n = 770), MGH (n = 701) and deCODE (n = 589). Histograms show the P-value distribution of trans genes in each replication cohort. d, The trans network is not present in other tissues in the same samples from the TwinsUK study that were used for the discovery made in adipose tissue. Histograms show P-value distribution of trans genes in skin (n = 716), lymphoblastoid cell lines (LCLs) (n = 814) and whole blood (n = 384). In the TwinsUK, METSIM and deCODE studies, the association between KLF14 lead SNP rs4731702 genotype and gene expression was assessed with linear models with correction for relevant covariates (see Methods) and with the Kruskal-Wallis test in the MGH dataset. Uncorrected P values are displayed. Trans-gene associations were considered replicated at a P value of < 0.05.
As methylation is one of the key processes related to enhancer function, we explored population-level methylation data at this locus in many of the same TwinsUK subjects. The T2D risk haplotype was associated with increased methylation levels at Illumina 450K array probe cg02385110, ~3 kb upstream of KLF14, in subcutaneous adipose tissue (n = 603, P = 2.2 × 10 −7 , and β = 0.01 for rs4731702) but not whole blood (n = 309; P = 0.69) or skin (n = 437; P = 0.39) (Fig. 1e-i ). There was a consistent direction of effect across these analyses in adipose: the T2D-risk haplotype was associated with increased methylation and decreased RNA expression, and cg02385110 methylation and KLF14 expression were negatively correlated. A second probe (cg08097417) located at the KLF14 transcription start site has been associated with age in whole blood 21 and adipose-tissue samples 22 . However, this probe lies outside the T2D-association interval, and cg08097417 methylation was not related to KLF14 expression (P = 0.36) or risk haplotype (P = 0.99), indicating that age-related variability of cg08097417 is unrelated to KLF14 expression or disease pathogenesis ( Supplementary Fig. 3 ). Instead, we conclude that T2D-associated risk attributable to this locus is probably a consequence of sequence variation at the adipose enhancer upstream of KLF14 and is marked by altered methylation.
The KLF14 variants regulate a large adipose tissue-specific trans network. The trans network regulated by the KLF14 variants is remarkable both for its size and its robust replication. Consistent with the known function of KLF14 as both a transcriptional activator and a transcriptional repressor, the trans associations included both positive effects and negative effects ( Fig. 2a and Supplementary Table 1) . Mediation analysis applied to the RNA-expression data supported the proposal of a causal role for KLF14 expression in the regulation of many of the trans genes (161 of 385 genes passed Bonferroni-corrected Sobel's mediation: P < 1.3 × 10
−4
). The principal trans-regulatory mechanism appeared to be direct interaction of KLF14 with trans-gene cis-regulatory elements; the 20-kb regions upstream of the 385 trans genes showed enrichment both for KLF14 binding peaks in empirical data obtained by chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) 23 of HEK293T human embryonic kidney cells (P = 2 × 10 −4 ) and the presence of the proposed KLF14 binding motif (normalized enrichment score (NES) = 4.17; P = 1.5 × 10 -5 ). We assessed functional annotation of the trans genes using ToppGene 24 and found the subset of 177 trans genes with KLF14-binding motifs to be enriched for the categories 'metabolic pathways' (P = 1.2 × 10 −3 (Bonferroni corrected)) and 'binding by PPARG and RXRA during adipocyte differentiation' (P = 3.9 × 10 −8 (Bonferroni corrected)) (Supplementary Table 5 ). Further sub-setting defining 122 trans genes enriched for both KLF14-binding motifs and KLF14 ChIP-seq peaks showed broadly similar functional enrichment ('binding by PPARG and RXRA during adipocyte differentiation' , P = 0.04 (Bonferroni corrected); and 'metabolic pathways' , P = 2.6 × 10 −4 (Bonferroni corrected)).
A sub-network of 18 trans genes showed enrichment for binding motifs for the transcription factor SREBF1 (NES = 4.22; P = 1.2 × 10 -5 ), 11 of which did not have KLF14 motifs (Fig. 2b) . The sub-network of SREBF1 motif-containing trans genes showed enrichment for the category 'cholesterol biosynthesis and lipid metabolism' (P = 2.8 × 10 −7 (Bonferroni correction)) (Supplementary Table 5 ). SREBF1, which encodes a transcription factor involved in cholesterol homeostasis, is itself a trans gene directly regulated by KLF14 and appears to act as an intermediary in the regulation of this sub-network.
The human trans network includes several genes encoding molecules with functions that make them attractive candidates for mediating the range of KLF14-associated phenotypes. These include SLC2A4 and IDE, which encode the glucose transporter GLUT4 and insulin-degrading enzyme IDE, respectively. GLUT4 mediates glucose uptake in adipose tissue and skeletal muscle, among other tissues, and an adipose tissue-specific reduction in the expression of SLC2A4 has been reported in T2D 25 . IDE degrades peptides, including insulin, glucagon and amylin, and maps to a long-established T2D GWAS interval 15 . Notably, at multiple trans genes, we identified adipose-tissue cis-eQTLs coincident with metabolic-trait GWAS SNPs (r 2 > 0.8), including three known T2D-associated loci (STARD10, C6orf57 and CDK2AP1) (Supplementary Table 6 ). This shows that local regulation of these genes can mediate susceptibility to T2D independently of trans regulation via KLF14 and indicates that the phenotypic consequences of KLF14 variation are probably mediated by multiple genes within the trans network. , emphasizing a primary impact on insulin action rather than on insulin secretion. By collecting data from the largest available GWAS meta-analyses for multiple traits 26 , [28] [29] [30] [31] , we extended the spectrum of KLF14 association to encompass a broad range of insulin-resistant, 'metabolic-syndrome' phenotypes, including such traits as low-density lipoprotein (LDL) cholesterol, triglycerides, waist/hip ratio (WHR) and fasting insulin 32 (Table 1) . Crucially, as demonstrated before 31 , the impact of KLF14 variation was far greater on fat distribution than on overall adiposity (as measured by body-mass index (BMI)), with a particularly strong association between the T2D risk allele and reduced hip circumference (β = -0.017; P = 1.6 × 10
−6
). Sex-stratified reanalysis of the GWAS data above showed that for all traits with available data, effect sizes in females substantially exceeded those in males ( Table 1 ). The associations with hip circumference, triglycerides, LDL and fasting insulin were exclusive to females, while the associations with HDL-C, WHR and T2D displayed a strong female bias (for example, T2D female, P = 2.2 × 10 −6 , odds ratio (OR) = 1.14 (1.08-1.20); T2D male, P = 0.002, OR = 1.08 (1.03-1.14)). In the UK Biobank (n = 118,192 subjects), we found significant SNP × sex interactions for hip circumference (P = 3.1 × 10
) and WHR adjusted for BMI (P = 3.9 × 10 ) but not for waist circumference (P = 0.06) or BMI (P = 0.43). In a combination of samples from the UK Biobank, Wellcome Trust Case Control Consortium and The Resource for Genetic Epidemiology on Adult Health and Aging (GERA) (13,728 cases; 129,911 controls), rs4731702 and sex interacted to influence T2D risk (P = 6.6 × 10
−3
). The analyses noted above demonstrate that the metabolic and anthropometric consequences of KLF14 variation are dependent on both the parental origin of the risk allele and the sex of the recipient of that allele. By combining these sex-specific ORs with the known imprinting-related maternal specificity of these associations 1 , we estimate that the per-allele OR for T2D is ~1.28 in women who inherited the risk allele from their mother. In contrast, although KLF14 expression in adipose tissue was higher in females than males across all genotype classes, we found no equivalent sex difference in the magnitude of the adipose-tissue cis-eQTL effect ( Fig. 3a and Supplementary Table 4 ). To further explore drivers of the sexual dimorphism in KLF14 expression, we compared KLF14 expression in 86 pre-menopausal females with that in 487 post-menopausal females from TwinsUK. Subjects on hormone-replacement therapy were excluded from this analysis. There was no association between KLF14 expression and menopausal status (P = 0.81), and the ciseQTL effect sizes in each group were similar, which suggested that gonadal steroids do not underlie the observed sexual dimorphism in KLF14 expression levels. We conclude that the sex dependency of the whole-body phenotype is not the direct consequence of sexual dimorphism at the cis-regulatory level.
The genetic associations were consistent with our observations using gene-expression levels in the TwinsUK cohort. KLF14 expression in adipose tissue was associated with a combined insulinresistance phenotype characterized by increased fasting insulin and triglycerides and decreased HDL-C (P = 1.08 × 10
). KLF14 trans genes also showed enrichment for association between trans-gene expression levels and the same combined insulin-resistance phenotype (P = 1.82 × 10 6 ) (Supplementary Tables 7 and 8 ). We used dualenergy X-ray absorptiometry (DXA)-derived body-composition data from the TwinsUK subjects for whom gene-expression data were available to further delineate the impact of KLF14 expression on fat distribution. While there was no association between KLF14 expression in subcutaneous adipose tissue and total fat volume (P = 0.56) or BMI (P = 0.27), there were differences in the distribution of that fat, including an inverse association with abdominal visceral fat (P = 0.02) and with the ratio of android fat to gynoid fat (P = 1.7 × 10
). In many other insulin-resistant settings, abnormalities in fat distribution are associated with ectopic deposition of fat, including deposition in the liver, which leads to non-alcoholic fatty liver disease. However, we found no evidence that KLF14 risk variants influence fat deposition in the liver, whether measured directly (P = 0.26; n = 7,176) 33 or indirectly via disturbed liver function (alanine aminotransferase, P = 0.79; gamma-glutamyl transferase, P = 0.89; n = 61,089) 34 . These data indicate that a genetically determined reduction in the cis expression of KLF14 in adipose results in an insulin-resistant and T2D-predisposing phenotype that, in women only, is characterized by (and potentially mediated through) a shift in fat distribution from relatively inert gynoid stores to deposition in more metabolically active abdominal tissues.
Conserved mouse phenotypes.
We generated mice carrying adipose tissue-specific deletion of a Klf14 allele through the combination of a CRISPR-Cas9-generated allele with Klf14-flanking loxP sites and adipose tissue-specific expression of Cre recombinase (via Adipoq) and compared those mice with their wild-type Cre-expressing colony mates. Mice of both sexes with adipose tissue-specific knockout of Klf14 (null on both maternal and paternal chromosomes) displayed a broad pattern of insulin-resistance phenotypes: HDL-C was reduced (16 weeks, significant only in The KLF14 cis-eQTL has a similar effect size in males (n = 265) and females (n = 376), but KLF14 expression is higher in females than in males across all genotype classes. Plots display relative expression of KLF14 (mean ± s.e.m.). b, Pre-adipocytes derived from abdominal biopsies and subjected to a 14-d differentiation protocol show higher KLF14 expression in females (n = 4; mean ± s.e.m.) than in males (n = 4; mean ± s.e.m.) at all time points.
females), triglycerides were increased (16 weeks, significant only in males) (Fig. 4a,b) , and both glucose tolerance and insulin sensitivity were impaired in both sexes at 12 weeks ( Fig. 4c-f ).
We also characterized two mouse lines in which Klf14 expression was reduced globally. The first mouse (Klf14 tm1(KOMP)Vlcg ; generated by the KOMP repository) featured deletion of the entire single exon of Klf14. The second mouse, designed to minimize any disruption of adjacent regulatory sequences, was generated by CRISPRCas9 genome editing to induce a 7-bp frameshift insertion-deletion allele. There were some inconsistencies between the models, but the predominant phenotype was a reduction in HDL-C (Supplementary Figs. 4a and 5a) with a modest and/or transitory effect on glucose homeostasis ( Supplementary Figs. 4b-d and 5d,e) . The HDL-C phenotype seen in the mice with global deletion of Klf14 mirrors the phenotype reported following hepatic tissue-specific deletion of Klf14
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.
RNA-seq analysis of subcutaneous fat taken, both from mice with adipose tissue-specific knockout of Klf14 and Klf14 tm1(KOMP)Vlcg mice with global deletion of Klf14, replicated some but not all of the features of the trans network seen in humans. In the mice with adipose tissue-specific knockout of Klf14 (n = 8), 87 genes were expressed differentially at an FDR q value of < 0.05 (or 1,286 genes with a P value of < 0.05). The latter set (of 1,286 nominally significant mouse genes) showed significant enrichment for overlap with the human trans network (P < 2 × 10
−4
). In the Klf14 tm1(KOMP)Vlcg mice with global deletion of Klf14 (n = 16), we confirmed this overlap (P < 1 × 10
with the human trans network) in the 285 genes expressed differentially relative to their expression in control mice (FDR q < 0.05): 5′ noncoding sequences for these genes also showed enrichment for the presence of the Klf14 binding motif (P < 0.001). Although Srebf2 (the mouse ortholog of SREBF1) is directly regulated by Klf14, we did not detect enrichment among the mouse differentially expressed genes for the Srebf2 motif. The mouse differentially expressed genes showed enrichment for relevant functional categories, including 'response to lipid' (q = 4.4 × 10 ) and 'regulation of cell proliferation' (q = 3.2 × 10 −3 ) (Supplementary Table 9 ).
Thus, adipose tissue-specific deletion of Klf14 in mice recapitulates many aspects of the phenotype associated with variants that influence adipose tissue-specific cis regulation of KLF14 in humans, but the absence of sex specificity and differences in the molecular consequences of Klf14 perturbation place limits on the relevance of mouse models for this gene.
KLF14 impacts glucose uptake, lipogenesis and cell size.
Members of the KLF family are involved in the transcriptional control of adipocyte development and function 5 , but the role of KLF14 in adipogenesis is unknown. To evaluate the role of KLF14 in adipocyte development, we measured KLF14 expression in primary pre-adipocytes isolated from biopsies of human abdominal subcutaneous adipose tissue (female, n = 4; male, n = 4) during proliferation and subsequent differentiation over 14 d. Adipocyte expression of KLF14 was higher in females than in males at all time points (Fig. 3b) , demonstrating that the sex-differential expression of KLF14 observed in adult biopsies is present throughout adipogenesis.
We next investigated the link between reduced expression of KLF14 and adipocyte development. Fresh adipose-tissue explants from females homozygous for the risk allele showed a 44% reduction in lipogenesis (P = 0.001; n = 132) relative to that of tissue from females homozygous for the non-risk allele, as measured by incorporation of the 14 C-glucose label into the triglyceride backbone (Fig. 5e ). There was no difference in males (P = 0.49; n = 32) (Fig. 5e) . We confirmed those findings in vitro through short hairpin RNA (shRNA)-mediated knockdown of KLF14 (40% at day 1, and 33% at day 14) (Fig. 5a ) in primary pre-adipocytes isolated from abdominal subcutaneous biopsies (n = 7 females); this resulted in a 60% reduction in the accumulation of triglycerides after 14 d of differentiation (P = 0.03) (Fig. 5c) . The adipocyte differentiation wholly relied on de novo lipogenesis, as the cell-culture medium contained glucose but not fatty acids. Knowing that SLC2A4 (which encodes GLUT4) is a KLF14 trans gene, we first assessed expression of GLUT4 in the KLF14-shRNA knockdown adipocytes that showed lower expression as compared to control non-targeting shRNA cells (by 64% ± 7% (mean ± s.e.m.); P = 0.02) (Fig. 5a) . To investigate the functional consequences of the reduction in GLUT4 expression, we quantified the insulin-stimulated uptake of glucose and found a 50% reduction in KLF14-shRNA knockdown adipocytes (Fig. 5d) . Concomitant with the lower glucose uptake and lipogenesis, the expression of genes encoding adipocyte-maturation factors (PLIN1 (-42% ± 8%; P = 0.02), LEP (-54% ± 13%; P = 0.03) and FITM2 (-12% ± 4%; P = 0.04)) was significantly lower in the Clinical chemistry parameters were measured in female and male C57BL/6 J mice with adipose tissue-specific (Adipoq-Cre) knockout of Klf14 (KO) and their Adipoq-Cre-expressing wild-type control counterparts (Wt). Mice were fed a standard diet throughout their lifetime. a, HDL-C at 16 weeks was significantly lower in the female knockout group mice than in wild-type mice (P = 0.04). b, Triglycerides at 16 weeks were significantly higher in the male knockout group than in wild-type mice (P = 0.03 (unpaired twotailed t-test)). c,d, Glucose levels (assessed by an intraperitoneal glucose tolerance test) at 12 weeks of age were significantly higher in female (c) and male (d) knockout mice than in wild-type control mice at multiple time points. e,f, In an insulin tolerance test at 12 weeks of age, glucose was reduced to a lesser extent in knockout mice than in their wild-type control counterparts at multiple time points in both females (e) and males (f). Pairwise significance as compared to controls is shown. Analysis in a,b used unpaired two-tailed t-tests (for male HDL-C, with Welch's correction), and those in c-f used two-way ANOVA with repeated measures and Bonferroni correction (GraphPad Prism 6). Wild-type mice are shown as blue lines and blue filled symbols (females n = 8 and males n = 8); knockout mice are shown in red lines and red filled symbols (females n = 5 and males n = 6). All error bars are plotted as a mean value ± s.d. cells in which KLF14 was knocked down, while the levels of genes encoding classical early-differentiation, pro-adipogenic transcription factors (CEBPA and PPARG2) were not changed (Fig. 5a) . Knockdown of KLF14 also increased cellular proliferation, observed as reduced doubling time (P = 0.02) (Fig. 5b) . We infer that reduced levels of KLF14 result in a defect in glucose uptake, which results in impaired adipocyte lipogenesis and maturation, and we propose that the increase in proliferation results from fruitless cycling at earlier stages of differentiation.
Adipocyte size is an important marker of adipose-tissue dysfunction and metabolic disease and, in some studies, has been predictive of insulin resistance and T2D independently of obesity [36] [37] [38] [39] [40] . We assessed the distribution of adipocyte size and cell number by histological analysis of biopsies of subcutaneous abdominal and gluteal adipose tissue from sex-, age-and BMI-matched pairs of subjects from the Oxford Biobank who were homozygous for either the risk haplotype or non-risk haplotype (n = 18 males and 18 females). At both tissue sites, there was a marked shift toward increased adipocyte size in subjects homozygous for the T2D risk haplotype: this was observed only for women (comparison of median values: abdominal tissue, P = 0.008; gluteal tissue, P = 0.02) (Fig. 6b,d ,e and Supplementary Fig. 6a-c) . We estimated, assuming spherical cell morphology, that for females, there was a twofold difference between the genotype groups in their adipocyte volume. Gluteal and abdominal tissue from females homozygous for the T2D risk haplotype also contained fewer total adipocytes (comparison of median values for adipocyte counts: abdominal tissue, non-risk allele homozygotes, 2.21 × 10 10 ± 0.31 × 10 10 , and risk allele homozygotes, 0.66 × 10 10 ± 0.19 × 10 10 (P = 0.04); gluteal tissue, non-risk allele homozygotes, 4.87 × 10 10 ± 0.93 × 10 10 , and risk allele homozygotes, 2.25 × 10 10 ± 0.58 × 10 10 (P = 0.04)). The cell-size findings and their sex specificity were confirmed by a different technique (measurement of the diameter of isolated adipocytes from collagenase-digested tissue) in an independent cohort of 28 females (P = 0.004) and 16 males (P = 0.78) also matched for age and BMI (Fig. 6c ). Expression of all genes was measured by real-time PCR in seven paired knockdown and control replicates (n = 7; mean ± s.e.m.). A significant decrease in expression was seen for KLF14, measured at days 1 and 14. There was no change in PPARG2 or CEBPA, which encode early differentiation markers, at day 14. A significant decrease in expression was seen for LEP and PLIN1, which encode late-stage differentiation markers, and for the trans genes FITM2 and GLUT4, which encode late-stage adipogenic molecules, at day 14. Statistical significance was assessed using a Wilcoxon signed-rank two-sided test. An asterisk marks statistical differences between knockdown adipocytes and control adipocytes for each gene (P ≤ 0.05). b, Pre-adipocytes isolated from female abdominal adipose-tissue biopsies (n = 7; mean ± s.e.m.) and treated with KLF14-specific shRNA have a significantly lower doubling time than that of their control counterparts treated with non-targeting shRNA. c,d, KLF14-shRNA knockdown adipocytes have significantly less accumulation of triglyceridesl (TAGs) (n = 7, mean ± s.e.m.) (c) and insulin-stimulated glucose uptake (n = 6, mean ± s.e.m.) (d) than non-targeting shRNA-control cells. Statistical significance was assessed using a Wilcoxon signed-rank two-sided test. e, Females homozygous for the KLF14 risk allele (CC) have significantly less lipogenesis, as measured in adipose explants, than that of subjects homozygous for the non-risk allele (TT) (female n = 132, male n = 32; mean ± s.e.m.). The minimum and maximum values of lipogenesis are presented with their whiskers; the line in the box represents the median. Statistical significance was assessed using an unpaired two-sided t-test.
Discussion
Our results show that T2D risk variants that lead to lower expression of KLF14 in adult adipose tissue are also implicated in a defect of adipogenesis that probably reflects impaired glucose uptake. The consequence of this defect appears to be a profound effect on the structure of subcutaneous adipose tissue characterized by the presence of fewer but larger adipocytes. We infer that carriers of the KLF14 risk allele are obliged to favor expansion of existing adipocytes to meet lipid-storage needs, which results in suboptimal fat storage and an increased risk of insulin resistance and T2D. This hypothesis of impaired fat storage is consistent with the elevated levels of circulating triglycerides observed in carriers of the KLF14 risk haplotype. Reduced expression of KLF14 in female carriers of the risk allele probably drives a shift in the distribution of adipose tissue between subcutaneous fat depots, favoring abdominal deposition over gluteal deposition. This results in loss of the relative protection against the metabolic consequences of adipose-tissue accumulation associated with adipose deposition in gynoid sites, which has been widely observed in epidemiological studies 41, 42 and is consistent with the observed association of the KLF14 T2D risk allele and human fat distribution.
We note that the sex specificity of the KLF14 risk alleles varies across biological domains: effects on adipocyte development and whole-body phenotypes were more marked in females despite the fact that cis-and trans-regulatory effects are shared between the sexes. The simplest explanation for this discordance is a threshold effect driven by the higher baseline expression of KLF14 in females, although it is also possible that males lack downstream processes (for example, those related to the hormonal environment) that mediate the response to KLF14. While the KLF14-T2D association was discovered through typical GWAS approaches, the remarkable specificity of this association-with respect to sex, parent of origin, ethnicity and tissue of action-is a reminder that risk prediction, or targeted medical treatment, based on genotype alone may fail to capture highly relevant aspects of biological complexity.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-018-0088-x. More than 100 cells were measured for each biopsy (n = 18 per sex). Statistical significance was assessed using a Wilcoxon signed-rank two-sided test. c, Adipocyte cell volume measured in dispersed adipocytes from collagenase-dispersed abdominal adipose tissue (female n = 28, male n = 16; mean ± s.e.m.), stratified by sex and genotype (minimum and maximum values are presented with their whiskers; the line in the box represents the median). Statistical significance was assessed using a Wilcoxon signed-rank two-sided test. d, Cumulative frequency distribution of adipocyte cell-surface area in females (n = 18), measured as in b. e, Cumulative frequency distribution of adipocyte cell-surface area in males (n = 18), measured as in b. 21 ) and rs10954284 (Morris et al. 30 and Mahajan et al. 15 ), all three of which are in perfect linkage disequilibrium in Europeans (r 2 = 1). The lead SNP for the HDL-C GWAS is rs4731702 (Teslovich et al. 28 and Willer et al.
27
). As rs4731702 is present on all commonly used genotyping arrays, we chose to report all results in this manuscript with respect to rs4731702, where C is the T2D risk allele and T is the non-risk allele.
TwinsUK gene expression. Biopsies and blood samples from 856 healthy female twins from the TwinsUK cohort were collected within the MuTHER project 44 , and RNA was sequenced as previously described 7 (see Supplementary Note 1 for further details of the TwinsUK data).
Cis-and trans-eQTL analysis. Cis-and trans-eQTL analysis was conducted in the TwinsUK RNA-seq data as follows. Exon read counts were corrected for technical covariates and family structure using a mixed-effects model, including insert size and mean GC content as fixed effects, and primer index, sample processing date, family and zygosity as random effects. Corrected residuals were used for all eQTL analyses. Cis-and trans-eQTL associations were conducted using the MatrixeQTL package 45 using a standard additive linear model, with BMI, age and age-squared included as covariates. A window size of 1 Mb was used for cis-eQTL analyses. A FDR 46 threshold of 5% was applied to trans-eQTL results, with FDR calculated using the qvalue package 47 in R version 3.1.1. The deCODE, METSIM and MGH cohorts were analyzed as previously described [8] [9] [10] .
Functional fine mapping. We used the chromatin states predicted by ChromHMM 43 using 127 reference epigenomes from the ENCODE 16 and Roadmap Epigenomics projects 17, 55 . ChromHMM segments the genome into 15 states using 5 chromatin marks (H3K4me3, H3K4me1, H3K36me3, H3K27me3, H3K9me3) with predictions ranging from active transcription start sites to repressed Polycomb complexes. The ChromHMM predicted enhancer spans a 1.6-kb region, ~4 kb upstream of KLF14 transcription start site (TSS), and harbors five of the T2D GWAS SNPs (rs12154627, rs6973807, rs6974400, rs6974288, rs11762784).
TwinsUK methylation data. Adipose tissue sample in 603 individuals (taken from the same biopsy as the RNA-seq data) and 309 whole-blood samples from the TwinsUK study were profiled on the Illumina Infinium HumanMethylation450 BeadChip previously 48, 49 . The following covariates were included in analyses: batch (beadchip), BS conversion efficiency (as assessed using the built-in BS conversion efficiency controls) and BS-treated DNA input. The association of age with methylation was examined using a linear mixed effect regression model (LME) adjusting for batch effects, BMI, and, family and zygosity structure. Blood methylation was additionally corrected for estimated cell counts. To compare methylation and expression levels, each was first adjusted for covariates, and Pearson's correlation performed on the residuals.
Trans-network mediation analysis. Significant mediation was determined by computing Sobel's test statistic 50 . To calculate the mediation score, the three following models were implemented Model 1:~β
Model 2:~β
Model 3:
= β −β β Mediation score 3 4 4 where Y = trans-gene expression, A = age, E = cis-gene expression, P = BMI, and G = cis-genotype. By conditioning on cis-gene expression (the mediator, E) we can determine if each, individual association detected in trans is regulated in cis or is independent by quantifying Δ β G.
Enrichment of KLF14 binding in trans genes by ChIP-seq analysis. We used the HEK293 KLF14 ChIP-seq data from Najafabadi et al. 51 . Genomic coordinates of the peaks of KLF14 binding (along with the summit position for each peak) identified in the ChIP-seq experiments were available in the supplementary data of Najafabadi et al. (http://hugheslab.ccbr.utoronto.ca/supplementary-data/ C2H2_B1H/). For the enrichment analysis for KLF14 binding, we used the summit position of the 18,652 distinct ChIP-seq peaks of KLF14 binding (filtered on a minimum Phred-like quality score of call confidence of 50) provided in these data.
An enrichment for KLF14 binding sites for the 385 genes with trans-expression association with the KLF14 locus (FDR < 5%) was evaluated by comparing the proportion of genes for which KLF14 binding sites were identified in the following two groups of genes: first, the 385 genes with trans-expression association with the KLF14 locus; and second, the remaining genes that were tested in the transexpression analysis (n = 18,678). Enrichment for KLF14 binding sites for the 385 genes with trans-expression association was further evaluated by performing 10,000 permutations of a random set of 385 genes sampled from the entire set of genes that was tested in the trans-expression analysis, and estimating the number of genes with KLF14 binding sites for each permutation.
iRegulon transcription factor-binding analyses. In order to find the KLF14 regulon (a transcription factor (TF) and its direct transcriptional targets, which contain common TF binding sites in their cis-regulatory control elements), we used the iRegulon cytoscape plugin 52 . The prediction of regulons consists of four steps. (1) Motif detection: this process relies on an offline scoring step of a sequence search space (10 kb or 20 kb around the TSS), whereby every gene in the human genome, along with orthologous sequences in ten other vertebrate genomes, is scanned with Cluster-Buster 53 for homotypic clusters of motifs using a library of nearly 10,000 position weight matrices (PWMs), resulting in a generanking list for each PWM. Enriched motifs are those motifs for which the input genes are enriched at the top of the ranking, using the area under the curve (AUC) of the cumulative curve. (2) Track discovery: this step also relies on an offline scoring step whereby every gene in the human genome is scored with around 1120 ChiP-seq tracks, generating a list of TFs according to the highest ChiP peak within the regulatory space. (3) Motif2TF mapping: the candidate TFs are prioritized by finding the optimal path from a motif to a TF, in a motif-TF network. (4) Target detection: for each enriched motif, the candidate targets are selected as the significantly highly ranked genes compared to the genomic background and to the entire motif collection as background.
Functional enrichment analysis. KLF14 trans genes were subdivided into three subsets on the basis of the presence of bindings motifs for KLF14, SREBF1 or neither. The three subsets were assessed for functional enrichment using ToppFun, part of the ToppGene package 24 . Results were corrected for multiple testing using the Bonferroni method, with enrichments considered significant at a Bonferronicorrected P value of < 0.05.
Overlap between KLF14 trans-regulated genes and published GWAS results.
The NHGRI-EBI GWAS catalog 54 (available at http://www.ebi.ac.uk/gwas, accessed November 2015) was filtered so as to retain signals meeting genome-wide significance (P < 5.0 × 10
−8
). Corresponding cis-eQTLs for each of the 385 KLF14 trans genes, including secondary, tertiary and quaternary cis-eQTLs sequentially conditioned on the lead cis-eQTLs at each locus (a total of 465 cis-eQTLs), were then cross-referenced against the NHGRI GWAS results, retaining at each KLF14 trans-gene locus those reported NHGRI associations within ± 250 kb of the relevant cis-eQTLs that showed moderate to high LD (r 2 ≥ 0.8) between the reported GWAS SNP and the respective cis-eQTL.
Association between KLF14 expression and TwinsUK metabolic traits. To determine if gene expression was associated to a concurrently measured phenotype of interest, expression of each exon was treated as a quantitative trait in a linear mixed effects model implemented using the lme4 package 51 . The linear mixedeffects model was adjusted for age, BMI and technical covariates (mean GC content and insert size mode) (fixed effects), family relationship (twin pairing), primer index and zygosity (random effects). Phenotypic data were treated as continuous independent traits and were inverse-normal-transformed. A full model with the phenotype fitted was compared to a null model (no phenotype) using a 1-d.f. ANOVA. An FDR was estimated using the package QVALUE to obtain q values that correspond to a controlled FDR 5%. TwinsUK metabolic phenotypes were measured at the same time-point as the biopsy and were collected as previously described 3 . Body-fat distribution traits were measured using dual-energy X-ray absorptiometry (DXA; Hologic QDR 4500 plus) with the standard protocol.
Trait-expression association enrichment analyses. The most significantly associated exon per gene was retained for all genes. Enrichment was assessed by comparing the number of genes significantly associated with each phenotype (at q < 0.05) within the set of KLF14 trans-genes (n trans-genes = 385) to the remaining genes not within the KLF14 trans-network (n genes = 18,716), using a Fisher's exact test.
Sex × SNP interaction analysis in large cohorts. Details of the data preparation, quality control and cohort specific analysis covariates for the UK Biobank, GERA and WTCCC/T2D data are provided in Supplementary Note 1. To evaluate the SNP × sex interaction effect of rs4731702 on anthropometric traits in the UK Biobank, we tested for association of the genotype with each inverse-normalized variable using linear regression with a main effect for SNP and SNP-by-sex interaction terms using an additive model. We adjusted for covariates: age, age 2 , sex, six (within UK) ancestry principal components, and array version used to measure genotypes. A maximum of 118,193 individuals (62,165 females and 56,027 males) with genotype and valid measurements of BMI, height, waist and hip were available for analysis. To evaluate the SNP-by-sex interaction effect of rs4731702 on risk of T2D, we considered a total of 13,728 T2D cases and 129,911 controls from three studies from populations of European ancestry. Sample and variant quality control was performed within each study (see Supplementary Note 1). Within each study, the variant was tested for T2D association under an additive model after adjustment for study-specific covariates, including principal components to adjust for population structure and with a main effect for SNP and SNP-by-sex interaction terms. We then combined association summary statistics for the variant across studies via fixed-effects inverse-variance weighted meta-analysis. Experimental design of in vivo mouse experiments in CRISPR-Cas9 mouse models. The CRISPR-Cas9 knockout mouse models were generated as described in Supplementary Note 1. All procedures used for CRISPR-Cas9 animal studies were approved by Harvard University's Faculty of Arts and Sciences Institutional Animal Care and Use Committee and were consistent with local, state, and federal regulations as applicable. All animals were housed in a 12-h dark-light cycle and were fed standard chow ad libitum in conditions similar to those described above. The control mice and knockout mice were littermates from several litters that were timed to be the same age; the mice were kept in the same cages, in as few cages as permitted by the restrictions set forth by institutional policy (typically no more than three adult mice per cage).
Animal experiment information. CRISPR-
For lipid measurements, blood samples were collected from the lateral tail vein following an overnight fast. Samples were kept on ice then centrifuged for 10 min at 2,000g in a centrifuge at 4 °C. The plasma levels of triglyceride, total cholesterol and HDL-C were measured using Infinity Triglycerides Reagent (Thermo Fisher), Infinity Cholesterol Reagent (Thermo Fisher) and HDL-Cholesterol E (Wako Diagnostics) independently according to the manufacturers' instructions. For the intraperitoneal glucose tolerance test (IPGTT), the mice were fasted overnight, and glucose concentrations were measured immediately before and at 20, 40, 60 and 120 min after intraperitoneal injection of glucose (1 g/kg body weight). For the insulin tolerance test (ITT), the mice were fasted for 4 h, and glucose concentrations were measured immediately before and at 20, 40, 60 and 120 min after intraperitoneal injection with human insulin (Sigma) at 1 U/kg body weight. Whole-blood glucose levels were measured using a glucose meter and test strips (OneTouch). For histological examination, fat tissue was fixed in 4% paraformaldehyde and embedded in paraffin. Consecutive sections were cut and stained by hematoxylin and eosin for light microscopy examination and evaluation.
Experimental design of in vivo mouse experiments in deletion mouse models. Klf14 tm1(KOMP)Vlcg deletion mice were generated as described in Supplementary Note 1. Deletion mice were kept under controlled conditions of light (light 7am-7 pm, dark 7pm-7am), temperature (21 ± 2 °C) and humidity (55 ± 10%). They had free access to water (9-13 ppm chlorine) and were fed a commercial diet (SDS Rat and Mouse No. 3 Breeding diet, RM3) ad libitum until 18 weeks of age, when they were then transferred to a high-fat diet (45% kcal from fat; D12451; Research Diets).
Cohorts of male and female mice were bred for longitudinal blood-and bodycomposition-based phenotyping tests. These included four groups: (1) MAT (heterozygotes (hets) inheriting the allele maternally), (2) PAT (hets inheriting the allele paternally), (3) WT MAT controls, and (4) WT PAT controls. Samplesize estimates were based on previous experience and data from other mouse models in which the relevant traits were measured. These data were used in power calculations to help in deciding cohort sizes. Mice were housed in single-sex groups of mixed genotype across multiple litters and were not randomized into groups. Mouse IDs and genotypes were recorded on the cages, and the operator carrying out the animal procedure were not blinded to these, although subsequent tests only include animal ID information and clinical chemistry was carried out by a core service without knowledge of the genotypes.
Echo-MRI analysis and fasted blood sampling from the lateral tail vein (local anesthetic) were carried out at 8, 12, 22 and 27 weeks of age. Whole-blood glucose was measured using an AlphaTRAK meter and test strips (Abbott). Plasma insulin was assayed using a Mouse insulin ELISA kit (Mercodia). Terminal blood samples were collected from 33-week-old mice by intraperitoneal anesthesia and cardiac puncture following an overnight fast. Samples were kept on ice then centrifuged for 10 min at 8,000 g in a centrifuge set to room temperature. The resulting plasma was analyzed on board a Beckman Coulter AU680 clinical chemistry analyzer using reagents and settings recommended by the manufacturer. Clinical biochemistry for cholesterol analysis was conducted on 8-, 22-, 27-and 33-week blood samples.
Statistical analysis of mouse data. Data collection, summary calculations and descriptive statistics were carried out using Microsoft Excel 2010. Statistical analysis was carried out using software Graphpad Prism v6. Effects of genotype at different time-points on clinical chemistry parameters were determined by two-way ANOVA with repeated measures and Bonferroni's correction for multiple comparisons. Unpaired two-tailed t-tests were used for pairwise comparisons as appropriate and variances were equal, except for Fig. 4a male data, in which a Welch's correction was applied for unequal variance. Datasets were tested for normal distribution and equal variance according to a D' Agostino-Pearson omnibus K2 normality test and a Brown-Forsythe test, respectively, in Graphpad Prism. Consequently, non-parametric tests were applied as necessary and are indicated in the figures. In these cases area under the curve was calculated (baselined to t = 0 values) and tested with either a one-way ANOVA KruskalWallis test and Dunns multiple comparison test where there were multiple groups (Klf14 tm1(KOMP)Vlcg knockout mice) or Mann-Whitney two-tailed t-test when there were only two groups (CRISPR-Cas kncokout). Furthermore, as indicated, individual pairwise comparisons were made using Mann-Whitney two-tailed t-tests and are shown in the figures.
Gene expression in mouse models. Mouse RNA-seq data were collected as described in Supplementary Note 1 and were analyzed by the in-house bioinformatics team at MRC Harwell using a previously described pipeline 55 . Functional enrichment for mouse differentially expressed genes was assessed using ToppFun 24 , with enrichment considered significant after FDR multipletesting correction (q < 0.05). MEME_chip was used to identify motifs that were significantly over-represented in DNase I-hypersensitivity hotspots upstream of mouse differentiated genes.
Isolation, culture and differentiation of pre-adipocytes. Abdominal subcutaneous adipose tissue (ASAT) biopsies were obtained from eight healthy subjects (four females and four males) recruited from the Oxford BioBank (OBB) (http://www.oxfordbiobank.org.uk), who were 30-50 years of age with a BMI ranging from 22 kg/m 2 to 27 kg/m 2 . The study was approved by Oxfordshire Clinical Research Ethics Committee (08/H0606/107 + 5), and all subjects gave written informed consent. Primary pre-adipocytes were isolated as previously described 56 and were cultured in DMEM/F12 Ham nutrient mixture (DMEM/ F12), 10% FBS, 2 mmol/L glutamine, 0.25 ng/ml fibroblast growth factor, 100 units/ml penicillin and 0.1 mg/ml streptomycin. Confluent pre-adipocytes were then stimulated for 14 days with an adipogenic cocktail comprising DMEM/F12, 2 mmol/L glutamine, 17 mmol/L pantothenate, 100 nmol/L human insulin, 10 nmol/L triiodo-l-thyronine, 33 mmol/L biotin, 10 mg/ml transferrin, 1 mmol/L dexamethasone, 100 units/ml penicillin, and 0.1 mg/ml streptomycin. For the first 4 days, 0.25 mmol/L 3-isobutyl-1-methylxanthine and 4 mmol/L troglitazone were added. The cells were harvested every day during proliferation and 14 days during differentiation.
RNA isolation and Real-time PCR in pre-adipocytes. Total RNA was extracted from pre-adipocytes as described 56 . Real-time PCR was performed on an Applied Biosystems 7900HT, using TaqMan Assays-on-Demand (Applied Biosystems) and Klear Kall Master Mix (KBiosciences). mRNA expression values for target genes were calculated using the DCt transformation method 57 . The DCt was calculated as follows: DCt = efficiency (minimum Ct -sample Ct). Values were normalized to endogenous control genes (PPIA and UBC) 58 .
Explant lipogenesis experiments. Adipocytes isolated from abdominal subcutaneous adipose tissue were used to measure activation of insulin-stimulated lipogenesis, as described in detail elsewhere 59 . In brief, isolated human adipocytes were incubated at a concentration of 2% (v/v) in Krebs-Ringer phosphate buffer (pH 7.4) containing albumin (40 mg/ml), [3-3H] glucose (5 × 10 5 dpm/ml), unlabeled glucose (1 μ mol/l) and varying concentrations of human insulin (0-70 nmol/l). The incubations were conducted for 2 h at 37 °C with air as the gas phase. Incubations were stopped by rapidly chilling the incubation vials to 4 °C, and the incorporation of radiolabeled glucose into adipocyte lipids (i.e. lipogenesis) was determined. Lipogenesis was expressed as the amount of glucose incorporated either per lipid weight of fat cells or per fat cell number, as described previously 59 .
Short hairpin RNA-mediated silencing of KLF14. KLF14 was silenced in primary pre-adipocytes derived from female ASAT. Lentiviral particles were produced by transient co-transfection of HEK293 cells, using a KLF14-specific short hairpin RNA (shRNA) lentiviral transduction construct (SHCLNV-NM_138693.1-255s1c1; Sigma-Aldrich) and non-targeting shRNA lentiviral constructs (SHC002V; SigmaAldrich) with packaging vectors (MISSION; Sigma-Aldrich). Cells were stably transfected by transduction of pre-adipocytes with lentiviral particles followed by selection in growth media containing 2 mg/ml puromycin.
Quantification of intracellular lipid content.
Control and KLF14-specific shRNA cell lysates were prepared in lysis buffer containing 1% IGEPAL-630, 150 mM NaCl and 50 mM Tris HCl. Lysates were sonicated and an aliquot was collected for protein quantification using the BioRad Dc Protein Assay kit. The remaining lysate was heated at 95 °C for 30 min, allowed to cool to room temperature, and then centrifuged at 12,000 g for 10 min. The triglyceride concentration in the supernatant was determined using a commercially available enzymatic kit (Instrumentation Laboratory UK) on an iLAB 650 Chemistry Analyser. Total triglycerides were normalized to protein concentration.
Estimation of cell doubling time.
Equal numbers of control and KLF14-specific shRNA cells were seeded in T75 flasks, 1.5 × 10 5 cells. Cells were trypsinized and double counted every 5 days. Doubling time was calculated using the formula T d = (t 2 − t 1 ) × [log(2) ÷ log(q 2 ÷ q 1 )], where t = time (days) and q = cell number.
Insulin-stimulated glucose uptake. Glucose uptake was assayed according to the established protocol from a commercial glucose uptake kit (J1342; Promega). The luminescent glucose uptake assay was applied to control and KLF14-specific shRNA-differentiated adipocytes in 96-well plates. In brief, differentiated cells were starved in hormone-free DMEM/F12 medium overnight. The medium was removed and the cells were washed with 100 μ l of phosphate-buffered saline (PBS), followed by incubation with 10 nM insulin for 1 h at 37 °C in 5% CO 2 . To initiate glucose uptake, 50 μ l of 2DG (1 mM) in PBS was added to the cells. The uptake reaction was stopped and the samples were processed as described in the manufacturer's protocol (J1342, Promega). All assay steps were performed at room temperature. All data were acquired on a PerkinElmer EnSpire 2300 multimode plate reader instrument, with an integration time of 0.5 s.
Adipocyte cell size and number study population and sample collection. Nine females and nine males carrying KLF14 risk allele and paired control subjects matched for age (30-50 years) and BMI (22-27 kg/m 2 ) were recruited from the OBB. Paired abdominal and gluteal subcutaneous adipose specimens were obtained by gun and needle biopsies. The gun biopsies were fixed in 10% paraformaldehyde, embedded in paraffin wax, cut into 5-µ m sections and stained with hematoxylin and eosin. Sections were viewed at 20 × magnification, and adipocyte crosssectional area was calculated using Adobe Photoshop 5.0.1 (Adobe Systems) and Image Processing Tool Kit (Reindeer Games). As previously described 60 , in order to accurately determine the minimum number of cells required for measurement of cell size distribution in a sample, we took four samples and counted 1,000 cells in each and observed that the coefficient of variation started to increase when fewer than 100 cells were included in each biopsy. Therefore, we included only biopsies with more than 100 cells available for quantification (n = 9 pairs from each genotype). Statistical significance was assessed using a Wilcoxon signed-rank test. Replication of the cell size was undertaken in a Swedish cohort 61 . Abdominal subcutaneous adipose specimens were obtained by needle biopsy. Adipocytes were separated from stroma cells by treatment in a shaking bath at 37 °C for 60 min with collagenase (0.5 mg/l) in 5 ml Krebs Ringer phosphate buffer (pH 7.4) with purified BSA (40 g/l) as previously described 59 . Adipocyte suspensions were then rinsed three times in collagenase-free buffer using nylon filters, and the cell sizes were measured by direct microscopy. The mean adipocyte diameter was calculated from measurements of 100 cells, and statistical significance assessed using a Wilcoxon signed-rank test. Cell numbers were calculated using the formula described 62 , where DXA-measured adipose depot size was divided by mean cell volume.
Life Sciences Reporting Summary. Further information on experimental design is available in the Life Sciences Reporting Summary.
Data availability statement. TwinsUK RNA-seq data are available from EGA (EGAS00001000805). TwinsUK adipose methylation data are available from ArrayExpress (E-MTAB-1866), and blood methylation data are available from GEO (GSE50660). TwinsUK genotypes are available upon application to the TwinsUK cohort. METSIM adipose array data are available from GEO (GSE70353).
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